In vitro cytokine release assays: Reducing the risk of adverse events in man

Bioanalysis

Volumn 3, Issue 23, 2011, Pages 2657-2663

  Kirton, Christopher M ^a   Gliddon, Daniel R ^a   Bannish, Gregory ^b   Bembridge, Gary P ^a   Coney, Lee A ^a  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

^b Huntingdon Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; OKT 3; RITUXIMAB; TGN 1412; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN PRESENTATION; BINDING AFFINITY; CELL ISOLATION; CHILL; CYTOKINE RELEASE; DISSEMINATED INTRAVASCULAR CLOTTING; DYSPNEA; EFFECTOR CELL; FEVER; HEADACHE; HUMAN; HYPOTENSION; IN VITRO STUDY; KIDNEY FAILURE; LUNG INFILTRATE; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; PROTEIN DETERMINATION; REVIEW; RIGOR; RISK REDUCTION; SIDE EFFECT; SPINAL PAIN; TACHYCARDIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; HUMANS;

EID: 82955193820     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.272     Document Type: Review

References (30)

1. Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2, and g-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47(4), 606-608 (1989). (Pubitemid 19110914)
2. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7), 2217-2224 (1999). (Pubitemid 29467667)
3. Wing MG, Moreau T, Greenwood J et al. Mechanism of frst dose cytokine-release syndrome by CAMPATH-1H: involvement of CD16 (FcgRIII) and CD11a/CD18(LFA-1) on NK cells. J. Clin. Invest. 98, 2819-2826 (1996). (Pubitemid 26427411)
4. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. Hematol. 81(1), 26-32 (2002). (Pubitemid 36075492)
5. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006). (Pubitemid 44343545)
6. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68(9), 1417-1420 (1999).
7. Albert D, Dunham J, Khan S et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann. Rheum. Dis. 67(12), 1724-1731 (2008).
8. Carpenter PA, Pavlovic S, Tso JY et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165 (11), 6205-6213 (2000).
9. Xu D, Alegre ML, Varga SS et al. In vitro characterization of fve humanized OKT3 effector function variant antibodies. Cell. Immunol. 1, 16-26 (2000). (Pubitemid 30170076)
10. Armour KL, Parry-Jones DR, Beharry N et al. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood 107(7), 2619-2626 (2006).
11. Kirton CM, Laukkanen ML, Nieminen A et al. Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-infammatory therapy. Eur. J. Immunol. 35(11), 3119-3130 (2005). (Pubitemid 41672517)
12. Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp. Cell Res. 317(9), 1278 (2011).
13. Stavenhagen JB, Gorlatov S, Tuaillon N et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv. Enzyme Regul. 48, 152-164 (2008).
14. Wilson NS, Yang B, Yang A et al. An Fcg receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 1(19), 101-113 (2011).
15. White AL, Chan HT, Roghanian A et al. Interaction with FcgRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754-1763 (2011).
16. Li F, Ravetch JV. Inhibitory Fcg receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. 6045, Science 333, 1030-1034 (2011).
17. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and infammation. Nat. Rev. Immunol. 10, 301-316 (2010).
18. Wing MG. Monoclonal antibody frst dose cytokine release syndromes-mechanisms and prediction. J. Immunotoxicol. 5(1), 11-15 (2008).
19. Bugelski PJ, Achuthanandam R, Capocasale RJ et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol. 5(5), 499-521 (2009).
20. Wing MG, Waldmann H, Isaacs J, Compston DA, Hale G. Ex vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther. Immunol. 2(4), 183-190 (1995). (Pubitemid 27433380)
21. Findlay L, Eastwood F, Stebbings R et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Meth. 352 (1-2), 1-12 (2010).
22. Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome. Curr. Opin Drug Discov. Devel. 13(1), 124-135 (2010).
23. Yang B, Pham TH, Goldbach-Mansky R, Gadina M. Accurate and simple measurement of the pro-infammatory cytokine IL-1b using a whole blood stimulation assay. J. Vis. Exp. 49, 2662 (2011).
24. Liebers V, Stubel H, Düser M, Brüning T, Raulf-Heimsoth M. Standardization of whole blood assay for determination of pyrogenic activity in organic dust samples. Int. J. Hyg. Environ. Health 212(5), 547-556 (2009).
25. Bruhns P, Iannascoli B, England P et al. Specifcity and affnity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113(16), 3716-3725 (2008).
26. ® and Mesoscale Discovery, for human cytokine profling. J. Immunol. Meth. 340 (11), 55-64 (2009).
27. Arvå E, Andersson B. Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand. J. Immunol. 49(3), 411-416 (1999).
28. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgRIIa and FcgRIIb receptors by human IgG wildtype and mutant antibodies. Mol. Immunol. 40 (9) 585-593 (2003). (Pubitemid 37329917)
29. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226-234 (2009).
30. van der Neut Kolfschoten M, Schuurman J, Losen M et al. Anti-infammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1507-1508 (2007).